Pharmafile Logo

ASC Therapeutics

- PMLiVE

2019: CRISPR and therapeutic gene editing comes of age

Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases?

- PMLiVE

Cutting through the noise: CRISPR

AstraZeneca looks to lead an R&D revolution as the company invests in CRISPR and functional genomics drug discovery

- PMLiVE

UniQure edges closer to haemophilia B gene therapy OK

The candidate could free patients from regulator injections of FIX products

- PMLiVE

Trial dents confidence in Sangamo’s gene-editing tech

Company proposing switch to next-gen version

- PMLiVE

J&J bolsters gene therapy unit with $100m MeiraGTx deal

Licenses two inherited retinal disorder candidates

- PMLiVE

Horizon taps academic partner to boost gene editing platform

Partners with Rutgers University to license base editing tech

Why precision medicine demands precision engagement

The speed of innovation brings its own challenges, says cloud computing expert

Navigating the antibiotic resistance crisis

Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Blue Latitude Health

- PMLiVE

Orchard plans IPO as gene therapy pipeline advances

UK biotech seeks funds for expanded rare disease portfolio

- PMLiVE

EMA to review Bluebird’s blood disorder gene therapy

LentiGlobin could free patients of regular blood transfusions

- PMLiVE

Genetic counsellors: the new healthcare influencers?

Blue Latitude Health explores the relationship between physicians and genetic counsellors, and the impact this has on turning precision medicine into a reality for oncology patients.

Blue Latitude Health

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links